Huang, Alexander C.
Postow, Michael A.
Orlowski, Robert J.
Mick, Rosemarie
Bengsch, Bertram
Manne, Sasikanth
Xu, Wei
Harmon, Shannon
Giles, Josephine R.
Wenz, Brandon
Adamow, Matthew
Kuk, Deborah
Panageas, Katherine S.
Carrera, Cristina
Wong, Phillip
Quagliarello, Felix
Wubbenhorst, Bradley
D’Andrea, Kurt
Pauken, Kristen E.
Herati, Ramin S.
Staupe, Ryan P.
Schenkel, Jason M.
McGettigan, Suzanne
Kothari, Shawn
George, Sangeeth M.
Vonderheide, Robert H.
Amaravadi, Ravi K.
Karakousis, Giorgos C.
Schuchter, Lynn M.
Xu, Xiaowei
Nathanson, Katherine L.
Wolchok, Jedd D.
Gangadhar, Tara C.
Wherry, E. John
Article History
Received: 14 June 2016
Accepted: 22 March 2017
First Online: 10 April 2017
Change Date: 27 April 2017
Change Type: Correction
Change Details: In Fig. 1c the x-axis label for the bottom bar graph was corrected.
Competing interests
: M.A.P. receives honoraria and/or research support from BMS, Merck, Novartis, Array, Infinity, and RGenix. J.D.W. receives honoraria and/or research support from Merck, BMS, and Genentech. T.C.G. receives honoraria and/or research support from BMS, Novartis, Merck, Incyte, and Roche. R.J.O. has anticipated employment at Merck. E.J.W. receives honoraria and/or research support from BMS, Merck, MedImmune, Surface Oncology, Takeda, and KyMab. E.J.W. has a patent licensing agreement for the PD-1 pathway.